{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-230201","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2025-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.939123+00:00","generated_at":"2026-05-17T04:42:06.530343+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Alnylam enters $500M revolving credit facility maturing 2030","bullets":["New $500M Revolving Credit Facility includes $150M letter of credit sublimit; available for working capital and general corporate purposes.","Interest rates: Term SOFR plus 1.50%–2.50% (based on Total Leverage Ratio); commitment fee 0.20%–0.35% on unused commitments.","Financial covenants: Total Net Leverage Ratio ≤ 3.75:1.00 and Consolidated Interest Coverage Ratio ≥ 3.00:1.00, tested quarterly.","Maturity September 30, 2030; springing maturity if outstanding Springing Maturity Debt exceeds $630M or 100% of EBITDA.","Guaranteed by material domestic subsidiaries and secured by substantially all assets, subject to customary exceptions and release conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-230201","json":"https://secwatch.observer/filing/0001193125-25-230201.json","markdown":"https://secwatch.observer/filing/0001193125-25-230201.md","text":"https://secwatch.observer/filing/0001193125-25-230201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/0001193125-25-230201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/d19737d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:42:06.530343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb12c31a2a3f80b9a121713083c0a559d97973c5","claim":"ALNYLAM PHARMACEUTICALS, INC. incurred revolving credit of $500.0 million revolving line of credit with Bank of America, N.A., as Administrative Agent at term SOFR rate plus an applicable margin between 1.50% and 2.50% maturing September 30, 2030.","evidence_excerpt":"“Credit Agreement”) among the lenders party thereto, Bank of America, N.A., as Administrative Agent, and the other parties named therein. The Credit Agreement provides for a $500.0 million revolving line of credit (the “Revolving Credit Facility”), including a $150.0 million letter of credit sublimit. The Credit Agreement provides that the Company has the right at","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/0001193125-25-230201-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$500.0 million revolving line of credit"},{"label":"Counterparty","value":"Bank of America, N.A., as Administrative Agent"},{"label":"Rate","value":"term SOFR rate plus an applicable margin between 1.50% and 2.50%"},{"label":"Maturity","value":"September 30, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}